BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 15306831)

  • 1. The pathophysiological basis for intensive insulin replacement.
    Rolla A
    Int J Obes Relat Metab Disord; 2004 Sep; 28 Suppl 2():S3-7. PubMed ID: 15306831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulation of the pancreatic islet-stress axis as a novel potential therapeutic target in diabetes mellitus.
    Ludwig B; Barthel A; Reichel A; Block NL; Ludwig S; Schally AV; Bornstein SR
    Vitam Horm; 2014; 95():195-222. PubMed ID: 24559919
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Type II diabetes mellitus.
    Edelman SV
    Adv Intern Med; 1998; 43():449-500. PubMed ID: 9506190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The importance of first-phase insulin secretion: implications for the therapy of type 2 diabetes mellitus.
    Del Prato S; Tiengo A
    Diabetes Metab Res Rev; 2001; 17(3):164-74. PubMed ID: 11424229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intensive insulin regimens: evidence for benefit.
    Bretzel RG
    Int J Obes Relat Metab Disord; 2004 Sep; 28 Suppl 2():S8-13. PubMed ID: 15306832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathophysiology of insulin secretion.
    Scheen AJ
    Ann Endocrinol (Paris); 2004 Feb; 65(1):29-36. PubMed ID: 15122089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of oral antidiabetic agents: why and when to use an early-phase insulin secretion agent in Type II diabetes mellitus.
    Standl E; Füchtenbusch M
    Diabetologia; 2003 Mar; 46 Suppl 1():M30-6. PubMed ID: 12652356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glucotoxicity and beta-cell failure in type 2 diabetes mellitus.
    Kaiser N; Leibowitz G; Nesher R
    J Pediatr Endocrinol Metab; 2003 Jan; 16(1):5-22. PubMed ID: 12585335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathophysiology of type 1 and type 2 diabetes mellitus: a 90-year perspective.
    Zaccardi F; Webb DR; Yates T; Davies MJ
    Postgrad Med J; 2016 Feb; 92(1084):63-9. PubMed ID: 26621825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reducing hypoglycaemia with insulin analogues.
    Heller S
    Int J Obes Relat Metab Disord; 2002 Sep; 26 Suppl 3():S31-6. PubMed ID: 12174321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel peptides under development for the treatment of type 1 and type 2 diabetes mellitus.
    Baron AD; Kim D; Weyer C
    Curr Drug Targets Immune Endocr Metabol Disord; 2002 Apr; 2(1):63-82. PubMed ID: 12477297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. beta-cell failure in diabetes and preservation by clinical treatment.
    Wajchenberg BL
    Endocr Rev; 2007 Apr; 28(2):187-218. PubMed ID: 17353295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Physiology of glucose homeostasis and insulin therapy in type 1 and type 2 diabetes.
    Ferrannini E
    Endocrinol Metab Clin North Am; 2012 Mar; 41(1):25-39. PubMed ID: 22575405
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of type 1 diabetes.
    Unger J
    Prim Care; 2007 Dec; 34(4):791-808, vi-vii. PubMed ID: 18061818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential role of oral thiazolidinedione therapy in preserving beta-cell function in type 2 diabetes mellitus.
    Walter H; Lübben G
    Drugs; 2005; 65(1):1-13. PubMed ID: 15610048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abnormalities in insulin secretion in type 2 diabetes mellitus.
    Guillausseau PJ; Meas T; Virally M; Laloi-Michelin M; Médeau V; Kevorkian JP
    Diabetes Metab; 2008 Feb; 34 Suppl 2():S43-8. PubMed ID: 18640585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progressive deterioration of beta-cell function in nonobese type 2 diabetic subjects. Postprandial plasma C-peptide level is an indication of insulin dependency.
    Prando R; Odetti P; Melga P; Giusti R; Ciuchi E; Cheli V
    Diabetes Metab; 1996 Jun; 22(3):185-91. PubMed ID: 8697306
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The natural history of diabetes with respect to disorders of insulin function].
    Dorner M; Pinget M; Brogard JM; Sapin R; Paris-Bockel D; Levy P; Jung C
    Journ Annu Diabetol Hotel Dieu; 1984; ():51-71. PubMed ID: 6399540
    [No Abstract]   [Full Text] [Related]  

  • 20. Beta- and alpha-cell dysfunction in type 2 diabetes.
    Del Prato S; Marchetti P
    Horm Metab Res; 2004; 36(11-12):775-81. PubMed ID: 15655708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.